Skip to main content
. 2022 Jun 3;46(5):701–712. doi: 10.4093/dmj.2022.0002

Fig. 1.

Fig. 1.

Annual prescription rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) according to the presence of atherosclerotic cardiovascular disease (ASCVD) or heart failure (HF). aThe presence of ASCVD or HF was determined whether the corresponding International Classification of Disease, 10th Revision (ICD-10) code presents in a given year regardless of hospitalization.